This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Friday, May 23, 2014
Tipping Point: The Unprecedented Hepatitis C Situation
Hepatitis C: A Brief Medical Primer
Rena Fox, Professor of Medicine, UCSF @UCSF
Tipping Point: The Unprecedented Hepatitis C Situation
Moderated By: James Hamblin, Senior Editor, The Atlantic
Richard Elion, Clinical Research Director, Whitman-Walker Health
Rena Fox, Professor of Medicine, UCSF
Donald Jensen, Director of the Center for Liver Diseases, University of Chicago
Steven Pearson, President, Institute for Clinical and Economic Review; Visiting Scientist, Department of Bioethics, National Institutes of Health
From AtlanticLIVE
Medicine, the Market, and You
We asked two industry experts a simple question: what are the market-based solutions to the high price of pharmaceuticals?
Source
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment